AI assistant
CATALYST PHARMACEUTICALS, INC. — Director's Dealing 2024
Jan 3, 2024
31542_dirs_2024-01-03_efc6cd0f-e652-4ec4-a7ff-5aeb9de0fe1d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK: 0001369568
Period of Report: 2024-01-01
Reporting Person: Daly Richard J (Director, President and CEO)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-01-01 | Options to purchase common stock | $13.30 | A | 1365319 | Acquired | 2031-01-01 | Common Stock (1365319) | Direct |
| 2024-01-01 | Restricted Stock Units | $ | A | 210526 | Acquired | Common Stock (210526) | Direct |
Footnotes
F1: Price of derivative security is based upon the date on which the Reporting Person's executed their offer letter (dated October 18, 2023) with the Registrant, in accordance with the Registrant's 2018 Stock Incentive Plan. Mr. Daly became the Registrant's President and Chief Executive Officer on January 1, 2024 and remains a member of the Registrant's Board of Directors.
F2: Derivative securities vest in five equal annual tranches beginning on January 1, 2025.
F3: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.
F4: Shares of common stock will be delivered to the Reporting Person upon vesting.